Autoinmunidad e Inmunodeficiencias
CTS150
Hospital Universitario Virgen del Rocío
Sevilla, EspañaPublications in collaboration with researchers from Hospital Universitario Virgen del Rocío (41)
2024
-
Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial
The Lancet Infectious Diseases, Vol. 24, Núm. 4, pp. 375-385
2021
-
Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials
BMC Infectious Diseases, Vol. 21, Núm. 1
2020
2019
-
Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects
Journal of Neuroimmune Pharmacology, Vol. 14, Núm. 3, pp. 413-422
2017
-
Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 36, Núm. 3, pp. 487-494
2016
-
Sarcoidosis: an update on current pharmacotherapy options and future directions
Expert Opinion on Pharmacotherapy, Vol. 17, Núm. 18, pp. 2431-2448
2015
-
Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 34, Núm. 9, pp. 1879-1884
2014
-
Are hip hemiarthroplasty and total hip arthroplasty infections different entities? The importance of hip fractures
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 33, Núm. 8, pp. 1439-1448
-
Atazanavir-based therapy with pegylated interferon and ribavirin for patients with hepatitis C and HIV
The Lancet Infectious Diseases
-
Clinical and virological efficacy of etravirine plus two active nucleos(t)ide analogs in an heterogeneous HIV-infected population
PLoS ONE, Vol. 9, Núm. 5
-
Liver fibrosis, host genetic and hepatitis C virus related parameters as predictive factors of response to therapy against hepatitis C virus in HIV/HCV coinfected patients
PLoS ONE, Vol. 9, Núm. 7
-
Predictors of early mortality in very elderly patients with bacteremia: A prospective multicenter cohort
International Journal of Infectious Diseases, Vol. 26, pp. 83-87
2013
-
Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis
Clinical Infectious Diseases, Vol. 56, Núm. 11, pp. 1646-1653
-
Reappraisal of the outcome of healthcare-associated and community-acquired bacteramia: A prospective cohort study
BMC Infectious Diseases, Vol. 13, Núm. 1
2012
-
Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients
Hepatology, Vol. 56, Núm. 4, pp. 1261-1270
-
Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients
AIDS, Vol. 26, Núm. 13, pp. 1721-1724
-
Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: A propensity score-based analysis
Antimicrobial Agents and Chemotherapy, Vol. 56, Núm. 1, pp. 472-478
-
Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis
Clinical Infectious Diseases, Vol. 55, Núm. 12, pp. 1719-1726
-
The undiagnosed cases of Clostridium difficile infection in a whole nation: Where is the problem?
Clinical Microbiology and Infection, Vol. 18, Núm. 7
2011
-
Análisis descriptivo de las enfermedades asociadas a bacteriemia por Streptococcus bovis
Medicina Clinica, Vol. 137, Núm. 12, pp. 527-532